The U.S. Food and Drug Administration (FDA) has today announced of its decision of permitting for the marketing of the first respirators that have been made in order to reduce the user's exposure to airborne germs during a public health medical emergency, such as an influenza pandemic. The two filtering facepiece respirators have been manufactured by St. Paul, Minn.-based 3M Company (and called the 3M Respirator 8612F and 8670F) and will be readily available to the general public and that also without a prescription, has been informed.

While talking to the concerned departments it has been revealed, that the National Institute for Occupational Safety and Health (NIOSH) devices has certified the devices as N95 filtering facepiece respirators. The NIOSH certifies respirators for use in occupational settings in accordance with an appropriate respiratory protection program. An N95 filtering facepiece respirator is a particular type of face mask that is required to be fitted tightly over the nose and mouth. The mask is made of fibrous material designed neatly for the sake of filtering out at least 95 percent of very small airborne particles. The filter and a proper fit have the potential to verify the effectiveness of the product.

It has come to the knowledge that HHS' Agency for Healthcare Research and Quality (AHRQ) has come up with a new and startling report. It has been stated by the report, that approximately one-fourth of all stays in U.S. community hospitals for patients age 18 and beyond amounting to 7.6 million of nearly 32 million are affected by the diseases like depressive, bipolar, schizophrenia and other mental health disorders or substance use related disorders in 2004.

The study is said to be regarded as the first instance of documentation of the detailed analysis of the impression of mental health and substance abuse disorders on U.S. community hospitals.  The report candidly speaks out of 1.9 million of the 7.6 million stays were for patients who were hospitalized primarily due to grave mental health or substance abuse problem. While in the other 5.7 million stays, though patients were primarily admitted for another condition, however in gradual course they were also diagnosed as being affected by a mental health or substance abuse disorder. The expense had to be made by the government and therefore nearly two-thirds of costs were billed to the government. Organizations like Medicare covered nearly half of the stays and about 18 percent were billed to Medicaid. Whereas 8 percent of the patients were uninsured. In addition, the private insurers were billed for the balance. One of every three stays of uninsured patients was related to a mental health or substance abuse disorder was also found out by the study.

The Food and Drug Administration (FDA) has been found in advising the general consumers for not to purchase or utilize "True Man" or "Energy Max" products that are promoted and sold as dietary supplements throughout the United States. It has been stated on behalf of FDA that both products hyped as sexual enhancement products and as treatments for erectile dysfunction (ED) are nothing but illegal drug products containing undeclared ingredients that are implied as harmful. After a thorough investigation, it has been found that the products contain substances known as analogs having similar structures to active ingredients in approved prescription drugs.

Having these concerns, the FDA is repeatedly requesting the consumers that they should discontinue the usage of True Man and Energy Max but with a prior consultation with their house physicians or medical practitioners about the approved treatments for ED.FDA encourages men who experience ED to seek guidance from a health care professional.

The escalation of diseases in the international arena in the recent years also has led to the increase of state initiatives for the sake of research and permanent healing. The same instance was repeated when the Hon’ble Governor of Massachusetts Deval L. Patrick announced of a state initiative that would provide the expenditure of a billion dollars over 10 years for fund various aspects regarding life science. It has been stated, that it would include fellowship grants, life science innovation centers, and a stem cell bank of new stem cell lines to be available for public and private research. The “Massachusetts Life Science Strategy” was unveiled at the BIO International convention in Washington.

It has come to the knowledge from the governmental sources, which thought behind the initiative has been to bring together various institutions viz. industry, academic research hospitals, and public and private colleges and universities for the coordination of these efforts.  Its encouragement shall also be in the stimulation of new researches, strengthening of investments, creation of new avenues for jobs along with the production of new therapies for a better quality of life.

It has been announced here today by NovaThera of England and Gamida Cell of Israel of a collaboration agreement that has been framed with the objective of developing cell therapeutic treatments for lung repair and regeneration. It has been stated according to the terms of the agreement that both of the NovaThera and Gamida Cell will be engaged in the combination of technology and expertise and alongside will also work together with the clinical team at Papworth Hospital in the U.K. towards the cause of improving cell therapy approaches for the treatment of lung disease.